LG
Ligand Pharmaceuticals Incorporated
LGNYZ · OTC
$0.04 -17.78% (-$0.01)
Market Cap $728.2K
P/E Ratio 0.02x
Div. Yield 2.08%
ROE 4.21%
Bulios Fair Price
$0.04
8.1% upside
Current Price
$0.037
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LGNYZ is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
5/9Valuation
100 /100
Cheap P/E 0.02x
P/FCF 0.02x
P/S 0.00x
Growth
77 /100
Growing Rev. growth 17.72%
Book val. growth 8.00%
EPS growth N/A
Profitability
51 /100
Moderate Gross margin 12.42%
FCF margin 12.27%
Net margin 14.26%
Quality
11 /100
Poor ROIC 0.64%
Asset turnover 0.17x
ROE 4.21%
Debt
96 /100
Low Debt/Equity 0.47x
Net debt/EBITDA -2.64x
Current ratio 24.69x
Stability
31 /100
Unstable Beta 0.98x
Profitable years 2
Rev. volatility 37.46%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LGNYZ
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Todd C. Davis
Employees
68
Headquarters
Jupiter